Onconetix (ONCO) Revenue — Quarter Ended Sep 30, 2025
Revenue in the reporting quarter increased markedly from the preceding quarter, but declined compared to the same quarter one year earlier. The sequential improvement reversed a previous downward trend, while the annual decrease indicates ongoing challenges.
Key takeaway
Quarter ended Sep 30, 2025 · FY2025 Q3
Revenue in the reporting quarter increased markedly from the preceding quarter, but declined compared to the same quarter one year earlier. The sequential improvement reversed a previous downward trend, while the annual decrease indicates ongoing challenges.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$303.7K
Revenue reported for this quarter.
Quarter-over-quarter
+185.1%
Change from the immediately preceding quarter.
Year-over-year
-25.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$1.2M
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2024 | $712K | n/a |
| Mar 31, 2025 | $101.6K | -85.5% |
| Jun 30, 2025 | $106.5K | -84.9% |
| Sep 30, 2025 | $303.7K | -25.4% |
Revenue performance
The quarter’s revenue rose sharply from the immediately preceding quarter. However, it remained below the level of the same quarter a year ago.
Quarterly comparison
Sequentially, revenue increased significantly versus the prior quarter. Year over year, revenue was lower than in the same period a year earlier.
What to watch
The sustainability of sequential revenue growth warrants attention given the company’s ongoing operating losses and reliance on external financing.